Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sertraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 0.85 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.85 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.85 |
| ▸ | MEN1 | O00255 | 4/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.85 |
| ▸ | NPC1 | O15118 | 2/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.85 |
| ▸ | MTOR | P42345 | 2/20 | 0.85 |
| ▸ | RAB9A | P51151 | 2/20 | 0.85 |
| ▸ | MLNR | O43193 | 1/20 | 0.85 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.85 |
| ▸ | ESR1 | P03372 | 1/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.85 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.85 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.85 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sertraline SCHEMBL7246621 | 0.99 | SLC6A4 (0.83) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL5391116 | 0.99 | MEN1 (0.85) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL29248769 | 0.96 | SLC6A4 (0.87) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL3022459 | 0.95 | SLC6A4 (0.85) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL5144859 | 0.93 | SLC6A4 (0.81) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL7922153 | 0.92 | MEN1 (1.00) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL3841967 | 0.92 | MEN1 (1.00) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL137619 | 0.92 | MEN1 (1.00) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL3856872 | 0.92 | MEN1 (1.00) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL14028076 | 0.92 | MEN1 (1.00) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114195881-B | Method for preparing sertraline acetate | 浙江湃肽生物股份有限公司 | 2022-09-16 | — | — | CN | claimed |
| CN-114829447-A | Brush prodrug and use thereof | 麻省理工学院 | 2022-07-29 | — | — | CN | claimed |
| CN-114195881-A | Method for preparing sertraline acetate | 浙江湃肽生物有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-212881191-U | Precipitate extraction element of acetate sertraline | 湖北健翔生物制药有限公司 | 2021-04-06 | — | — | CN | claimed |
| CN-212425697-U | Filter equipment is used in production of acetic acid semorelin | 南京星银药业集团有限公司 | 2021-01-29 | — | — | CN | claimed |
| JP-4791970-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| US-7893300-B2 | Process for the preparation of polymorphs of selective serotonin reuptake inhibitor | CIPLA LIMITED (IN) | 2011-02-22 | — | — | US | claimed |
| EP-1682483-B1 | PROCESS FOR THE PREPARATION OF POLYMORPHS OF SERTRALINE HYDROCHLORIDE | CIPLA LTD (IN) | 2010-05-26 | — | — | EP | claimed |
| US-20070135524-A1 | Process for the preparation of polymorphs of selective serotonin reuptake inhibitor | CIPLA LIMITED (IN) | 2007-06-14 | — | — | US | claimed |
| CN-1907268-A | Sertraline salts and sustained-release dosage forms of sertraline | PFIZER (US) | 2007-02-07 | — | — | CN | claimed |
| US-20040208926-A1 | Solubilized sertraline compositions | PFIZER INC | 2004-10-21 | — | — | US | claimed |
| JP-2003518487-A | — | — | 2003-06-10 | — | — | JP | claimed |
| US-6517866-B1 | Oral administration at controlled rate; side effect reduction | PFIZER INC. | 2003-02-11 | — | — | US | claimed |
| EP-1239839-A2 | HYDROGEL-DRIVEN LAYERED DRUG DOSAGE FORM COMPRISING SERTRALINE | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | claimed |
| US-20010044474-A1 | Hydrogel-driven layered drug dosage form | BEND RESEARCH, INC. | 2001-11-22 | — | — | US | claimed |
| WO-2001047498-A2 | HYDROGEL-DRIVEN LAYERED DRUG DOSAGE FORM COMPRISING SERTRALINE | PFIZER PRODUCTS INC. (US) | 2001-07-05 | — | — | WO | claimed |
| JP-2000514101-A | — | — | 2000-10-24 | — | — | JP | claimed |
| CN-1261793-A | Sertraline salts and sustained release dosage forms of sertraline | PFIZER (US) | 2000-08-02 | — | — | CN | claimed |
| EP-0999830-A1 | SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE | PFIZER INC. (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999001121-A1 | SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE | PFIZER INC. (US) | 1999-01-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044474-A1 | Hydrogel-driven layered drug dosage form | HTR3D, HTR5A, HTR3A | SLC6A4 5/4885SLC6A2 21/4885SLC6A3 23/4885 |
| US-20070135524-A1 | Process for the preparation of polymorphs of selective serotonin reuptake inhibitor | SLC6A4, HTR5A, HTR3B | SLC6A4 1/4885SLC6A2 6/4885SLC6A3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.